Expert Consensus Aims to Improve Access to CAR T-Cell Therapy

Published on: Cytotherapy

CAR T-cell therapy has transformed outcomes for aggressive B-cell Non-Hodgkin lymphoma, yet many eligible patients miss out due to delays in identification and referral. A newly published Delphi consensus outlines strategies to standardize early diagnosis, enhance collaboration between centers, and overcome logistical barriers. The goal is to ensure timely and equitable access to this life-changing treatment across diverse healthcare systems.

👉 Read the full article: Expert Consensus on Improving CAR T-Cell Therapy Access

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.